Retrospective analysis on treatment outcome of chronic HCV infected patients, the experience with DAAs at Addis Ababa, Ethiopia from January 2018 to January 2020.

No Thumbnail Available



Journal Title

Journal ISSN

Volume Title


Addis Abeba University


Background: HCV is a multisystem disease with significantly increased morbidity and mortality. Around 130-150 million people are chronically infected with HCV worldwide. The genotypic distribution of HCV is variable geographically and treatment outcome with DAAs inturn is variable. Objectives: to assess the treatment outcome of chronic HCV infected patients treated with DAAs at TASH and Adera specialty clinic, Addis Ababa, Ethiopia. Methods and Materials: A retrospective study was conducted to describe treatment outcome of chronic HCV infected patients treated with DAAs at TASH and Adera Specialty clinic from January 2018 to January 2020. All patients treated with DAAs over the study period and accessible clinical data were included in this study. Data was analyzed by using the latest SPSS version 26. Result: a total of 84 patients were included, 47(56.0%) of whom were females and mean age of 49±10.6 years. Viral genotype was documented for 51(60.7%) patients and 39(76.5%) of them had genotype 4. Diabetes and Hypertension were the commonest comorbidities identified in this study being present in 16.7% and 21.4% of cases respectively. Seventy-seven (91.7%) patients were treatment naïve and 34(40.5%) had evidence of liver cirrhosis based on imaging findings. Overall SVR12 was achieved in 76 (90.5%) patients. SVR12 occurred in 93.5% of patients who are non-cirrhotic and 83.5% of patients who are cirrhotic. APRI score of ≥ 0.7 was found to be associated with non-response to therapy. Fatigue and Nausea were the commonest side effects identified in 17.9% of patients with no reported life-threatening complications. Conclusion: Treatment of chronic HCV infected Ethiopian patients with DAAs resulted in high SVR12 rate with minimal safety concerns. Grant source: Addis Ababa University (AAU), college of health sciences, school of medicine.



Hepatitis C virus, Direct antiviral agents, SVR, TASH.